Sagimet Biosciences
SGMT
63 hedge funds and large institutions have $54.4M invested in Sagimet Biosciences in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 29 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.79% less ownership
Funds ownership: 68.86% → 64.07% (-4.8%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
23% less funds holding
Funds holding: 82 → 63 (-19)
24% less capital invested
Capital invested by funds: $71.6M → $54.4M (-$17.1M)
60% less call options, than puts
Call options by funds: $206K | Put options by funds: $515K
66% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$812K |
| 2 |
Two Sigma Investments
New York
|
+$338K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$315K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$308K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$288K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.48M |
| 2 |
RI
RTW Investments
New York
|
-$1.71M |
| 3 |
Millennium Management
New York
|
-$1.18M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$770K |
| 5 |
Jane Street
New York
|
-$519K |
SGMT Hedge Fund Activity: Q3 2024 in Review
63 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sagimet Biosciences (SGMT) for Q3 2024, worth a combined $54.4M — down 24% from $71.6M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SGMT and 10 opened new positions — a net loss of 19 holders — while 20 trimmed existing stakes and 16 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $812K. The largest seller was Artal Group, exiting entirely with an estimated $2.48M sold.
- 63 institutional investors held Sagimet Biosciences (SGMT) as of Q3 2024, down from 82 in Q2 2024.
- Funds reported $54.4M of Sagimet Biosciences stock for Q3 2024, down 24% quarter-over-quarter.
- 10 funds opened new Sagimet Biosciences positions in Q3 2024 and 29 closed out, a net change of -19 holders.
- The largest Sagimet Biosciences buyer in Q3 2024 was Marshall Wace, an estimated $812K added.
- The largest Sagimet Biosciences seller in Q3 2024 was Artal Group, an estimated $2.48M sold.
Based on aggregated 13F filings for Q3 2024.